IL-33 Antibody ( FITC ) (Cytokine)

IL-33 Antibody Datasheet

IL-33 Antibody Product Information

• Immunogen: Recombinant Human IL-33 protein (Catalog#10368-HNAE)
• Reagents: FITC-conjugated mouse monoclonal antibody
• Clone ID: 03
• Ig Type: Mouse IgG2b
• Concentration: 10 μl/Test, 0.1 mg/ml
• Formulation: Aqueous solution containing 0.5% BSA and 0.09% sodium azide
• Preparation: This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human IL-33 (rh IL-33; Catalog#10368-HNAE; NP_254274.1; Ser 112-Thr 270) and conjugated with FITC under optimum conditions, the unreacted FITC was removed.

IL-33 Antibody Usage Guide

• Specificity: Human IL-33
• No cross-reactivity in ELISA with
  

  Human cell lysate (293 cell line)

• Flow Cytometry:
  

  Flow cytometric analysis of Human IL-33 on HUVEC cells. HUVEC cells were treated according to manufacturer’s manual (BD Pharmingen™ Cat. No. 554714), and stained with FITC Mouse anti-IL-33 (Bold line hisgram).

  Flow cytometry was performed on a BD FACSCalibur flow cytometry system

  Please refer to www.sinobiological.com/Flow-Cytometry-FACS-Protocols-a-750.html for technical protocols.

• Storage: This antibody is stable for 12 months from date of receipt when stored at 2℃- 8℃. Protected from prolonged exposure to light. Do not freeze !
  Sodium azide is toxic to cells and should be disposed of properly. Flush with large volumes of water during disposal.

IL-33 Antibody Background

Interleukin-33 (IL-33), initially discovered as a nuclear factor NF-HEV abundantly expressed in high endothelial venules, also known as DVS 27, is a proinflammatory protein and a chromatin-associated cytokine of the IL-1 family with high sequence and structural similarity to IL-1 and IL-18. IL-33 is expressed highly and rather selectively by high endothelial venule endothelial cells (HEVECs) in human tonsils, Peyers's patches, and lymph nodes. It contains a bipartite nuclear localization signal at the C-terminus, and is targeted to the nucleus when ectopically expressed in human umbilical vein endothelial cells (HUVECs) and HeLa cells. The C-terminal fragment, corresponding to mature IL-33, binds and triggers signaling. IL-33 mediates its biological effects via Toll-interleukin 1 (IL-1) receptor (TIR) domain-containing receptor ST2, activates NF-kappaB and MAP kinases, and drives production of T (H)2-associated cytokines from in vitro polarized T (H)2 cells. In vivo, IL-33 induces the expression of IL-4, IL-5, and IL-13 and leads to severe pathological changes in mucosal organs.

References

1. Cayrol C,Girard JP, 2009, Proc Natl Acad Sci U S A. 106 (22): 9021-6.
2. Carriere V, et al., 2007, Proc Natl Acad Sci U S A. 104 (1): 282-7.
3. Baekkevold, E.S. et al., 2003, Am. J. Pathol. 163:69.
4. Schmitz, J. et al., 2005, Immunity. 23:479.
5. Black, R.A. et al., 1989, J. Biol. Chem. 264: 5323.
6. Xu, D. et al., 1998, J. Exp. Med. 187: 787.
7. Dinarello, C.A., 2005, Immunity. 23: 461.